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Neuroinflammation constitutes a fundamental process involved in Parkinson’s disease
(PD). Microglial cells play a central role in the outcome of neuroinflammation and
consequent neurodegeneration of dopaminergic neurons in the substantia nigra.
Current evidence indicates that CD4+ T-cells infiltrate the brain in PD, where they
play a critical role determining the functional phenotype of microglia, thus regulating
the progression of the disease. We previously demonstrated that mice bearing
dopamine receptor D3 (DRD3)-deficient CD4+ T-cells are completely refractory to
neuroinflammation and consequent neurodegeneration induced by the administration
of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In this study we aimed to
determine whether DRD3-signalling is altered in peripheral blood CD4+ T-cells obtained
from PD patients in comparison to healthy controls (HC). Furthermore, we evaluated
the therapeutic potential of targeting DRD3 confined to CD4+ T-cells by inducing
the pharmacologic antagonism or the transcriptional inhibition of DRD3-signalling
in a mouse model of PD induced by the chronic administration of MPTP and
probenecid (MPTPp). In vitro analyses performed in human cells showed that the
frequency of peripheral blood Th1 and Th17 cells, two phenotypes favoured by
DRD3-signalling, were significantly increased in PD patients. Moreover, naïve CD4+
T-cells obtained from PD patients displayed a significant higher Th1-biased differentiation
in comparison with those naïve CD4+ T-cells obtained from HC. Nevertheless, DRD3
expression was selectively reduced in CD4+ T-cells obtained from PD patients.
The results obtained from in vivo experiments performed in mice show that the
transference of CD4+ T-cells treated ex vivo with the DRD3-selective antagonist
PG01037 into MPTPp-mice resulted in a significant reduction of motor impairment,
although without significant effect in neurodegeneration. Conversely, the transference of
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CD4+ T-cells transduced ex vivo with retroviral particles codifying for an shRNA
for DRD3 into MPTPp-mice had no effects neither in motor impairment nor in
neurodegeneration. Notably, the systemic antagonism of DRD3 significantly reduced
both motor impairment and neurodegeneration in MPTPp mice. Our findings show a
selective alteration of DRD3-signalling in CD4+ T-cells from PD patients and indicate that
the selective DRD3-antagonism in this subset of lymphocytes exerts a therapeutic effect
in parkinsonian animals dampening motor impairment.
Keywords: neuroinflammation, neurodegeneration, Parkinson’s disease patients, MPTP mouse model, dopamine
receptors, CD4+ T-cells
INTRODUCTION
Several lines of evidence have indicated that neuroinflammation
plays a pivotal role in the development of Parkinson’s
disease (PD) (1). Microglial cells constitute the central
players in neuroinflammation, thereby their functional
phenotype determines whether surrounding neurons survive or
die. In this regard, depending on the integration of molecular
cues, microglial cells may acquire either a neurotoxic or a
neuroprotective phenotype, which are known as M1 and M2,
respectively (2).
Growing evidence in human and animal models has shown
the generation of nitrated forms of α-synuclein in the substantia
nigra (SN) of individuals with PD (3–5), which is mainly
contained in protein inclusions called Lewy bodies. Of note,
the nitration of α-synuclein, which is a consequence of the
oxidative stress, results in the generation of neo-antigens (1).
Furthermore, studies in mice and recently in humans, have
shown that oxidised α-synuclein constitutes a major antigen for
the T-cell-mediated immune response involved in PD (4, 6–
8). In this regard, it has been shown that nitrated α-synuclein
generated in the SN is captured and presented by antigen-
presenting-cells (APCs) in cervical lymph nodes to naive CD4+
T-cells with specificity to this neo-antigen. Once activated,
CD4+ T-cells acquire inflammatory phenotypes, such as T-
helper-1 (Th1) and Th17, then they infiltrate the SN where
microglial cells act as local APCs presenting nitrated α-synuclein-
derived antigens on class II MHC, thus re-stimulating T-cells
(4, 9–11). Re-stimulated CD4+ T-cells produce high local levels
of IFN-γ and TNF-α, thus promoting further inflammatory
activation of microglial cells (M1-microglia) (2, 12, 13). Activated
M1-microglia produces several neurotoxic and inflammatory
mediators, including reactive oxygen and nitrogen species, which
in turn induce neuronal death and further generation of oxidised
and nitrated proteins (1). Thus, this mechanism constitutes a
vicious cycle, which results in chronic neuroinflammation and
represents the engine of the progression of neurodegeneration.
Of note, several studies have shown that CD4+ T-cells deficiency
results in a complete protection of neurodegeneration in mouse
models of PD (4, 13, 14), thus indicating that inflammatory
CD4+ T-cell response is required to promote neurodegeneration
of the nigrostriatal pathway.
During last 15 years, several studies have shown dopamine
as a major regulator of inflammation (15–17). In this regard,
it has been consistently demonstrated that dopaminergic
signalling mediated by low-affinity dopamine receptors,
including dopamine receptors D1 (DRD1) and DRD2 exerts
anti-inflammatory effects in several experimental systems
(15, 16, 18). On the other hand, recent studies addressing
the role of dopaminergic regulation of CD4+ T-cells have
shown genetic and pharmacologic evidence indicating
that the stimulation of high-affinity dopamine receptors,
including DRD3 and DRD5, favours the acquisition of
Th1 and Th17 phenotypes, respectively, thus promoting
inflammation (19–21).
Since dopaminergic neurons are the main cells affected in PD,
dopamine levels are strongly reduced in the brain of PD patients
and animal models (14, 22). Thereby, dopaminergic signalling
mediated by low-affinity dopamine receptors is favoured in the
nigrostriatal pathway of healthy individuals, whilst the selective
stimulation of high-affinity dopamine receptors is promoted
in PD (17). In this regard, our previous results have shown
that DRD3-signalling in CD4+ T-cells plays a fundamental
role in the development of neurodegeneration in a mouse
model of PD induced by the administration of 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (13). Accordingly,
the genetic deficiency of DRD3 strongly limited the acquisition
of the inflammatory potential of CD4+ T-cells infiltrating the
SN of MPTP-treated mice, abrogating neurodegeneration of the
nigrostriatal pathway. Furthermore, the systemic administration
of a DRD3-antagonist resulted in a significant attenuation
of both neurodegeneration and motor impairment in MPTP-
treated mice (23). According to the relevance of DRD3-
signalling in animal models of PD, it has been shown a
significant association of PD-progression with the reduction of
the Drd3-transcription in peripheral blood mononuclear cells
(PBMCs) obtained from PD patients (24). Thus, current evidence
Abbreviations: Ab, Antibody; APC, antigen-presenting cells; DRDn, Dopamine
receptor n; Foxp3, forkhead box P3; GFP, green fluorescent protein; GFAP,
Glial Fibrillary Acidic Protein; IFN-γ, interferon γ; IL-n, interleukin n; mAb,
monoclonal Ab; MFI, mean fluorescence intensity; MoCA, Montreal Cognitive
Assessment; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; pAb,
polyclonal Ab; PBMCs, peripheral blood mononuclear cells; PE, phycoerythrin;
PD, Parkinson’s disease; PMA, phorbol 12-myristate 13-acetate; RAG1,
recombination-activating-gen-1; RAG1KO, RAG1 knockout; SN, substantia
nigra; SNpc, SN pars compacta; Thn, T helper n; TLRs, Toll like receptors; TLRn,
Toll like receptor n; TNF-α, Tumor Necrosis Factor α; Tregs, regulatory T cells;
UPDRS, Unified Parkinson’s Disease Rating Scale.
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suggests that DRD3-signalling in lymphocytes plays a relevant
role favouring the development of PD in animal models and
human individuals.
In this study, we addressed the question of whether DRD3
expression is altered in CD4+ T-cells obtained from PD patients
and how it is associated with the inflammatory phenotypes of
these cells. Furthermore, we evaluated the therapeutic potential
of the inhibition of DRD3-signalling confined to CD4+ T-
cells using an animal model of PD induced by the chronic
administration of MPTP.
MATERIALS AND METHODS
Human Subjects
Forty-one patients from both genders (22 females and 19
males) who meet Diagnostic Criteria of the Brain Bank of the
Society of Parkinson’s Disease in the UK (UK PDSBB) were
recruited from Hospital del Salvador. Demographic information
was collected and summarized in Table 1. Cognitive impairment
was evaluated by Montreal Cognitive Assessment (MoCA)
test and disease severity was determined with both Unified
Parkinson’s Disease Rating Scale (UPDRS) and Hoehn and Yahr
stages. The functional capacity was obtained as the Schwab and
England score. Patients with acute inflammatory or infectious
diseases, with chronic inflammatory or autoimmune diseases,
with hepatic damage, renal damage, fasting hyperglycemia, or
cancer and other diseases that might produce altered immunity
were excluded from this study. Thirty-eight age-matched healthy
controls (HC) chosen under the same exclusion criteria were
included in the study. Venous blood samples were obtained in
universal tubes containing heparin. Tubes were subsequently
coded and stored at room temperature until processing, which
occurred within 2 h after collection.
Flow Cytometry Analysis of Peripheral
Blood Immune Cells From Human
Individuals
Human PBMCs were obtained immediately after the extraction
of heparinized blood from HC or PD patients using Ficoll-
PaqueTM Plus (Ge Healthcare). PBMCs were immediately
analysed or activated with anti-human CD3 monoclonal
antibody (mAb; 2µg/ml, Biolegend) and anti-human CD28mAb
TABLE 1 | Demographic features and disease activity of Parkinson’s disease
patients.
Gender (Female/Male) 41 (22/19)
Age 65.6 ± 12.2
MoCA testa 27 ± 3.2
UPDRSb 31 ± 21.2
Hoehn and Yahrc 2.1 ± 0.97
Schwab and Englandd 80 ± 18.8
a Montreal Cognitive Assessment (scale 0–30).
bUnified Parkinson’s Disease Rating Scale (scale 0–199).
cModified Hoehn and Yahr scale (scale 0–5).
dSchwab and England activities of daily living scale (%).
(2µg/ml, Biolegend) in medium XVIVO-10 (Lonza) containing
1% autologous serum for 3d at 37◦C and 5% CO2. The
expression of DRD3 was analysed in different CD4+ T-cell
subsets, including total CD4+ T-cells (CD3+CD4+), naive CD4+
T-cells (CD3+CD4+CD45RA+CD45RO−) and effector/memory
(CD3+CD4+CD45RA−CD45RO+). DRD3 expression was also
analysed in B cells and natural killer (NK). For this purpose
immunostaining for surface markers was performed using the
following fluorophore-conjugated mAbs: Brilliant violet 421-
conjugated anti-CD3 mAb (1:100, Biolegend), FITC-conjugated
anti-CD4 mAb (1:100, Biolegend), PECy7-conjugated anti-
CD45RO mAb (1:100), Biolegend), APC-Cy7-conjugated anti-
CD45RA mAb (1:100, Biolegend), PE-Cy7-conjugated anti-
CD56 mAb (1:100, Biolegend), APC-Cy7-conjugated anti-CD19
mAb (1:100, Biolegend) and PE-Cy5-conjugated anti-CD25mAb
(1:100, Biolegend). To determine DRD3 expression we used a
primary polyclonal antibody (pAb) anti-DRD3 IgG antibody
developed in rabbit (2µg/ml, Abcam), and a secondary PE-
conjugated goat anti-rabbit IgG (Santa Cruz Biotechnology). As
an isotype control, irrelevant rabbit polyclonal IgG (2µg/ml,
Abcam) was used instead the anti-DRD3 pAb. To study T-
cell phenotypes, resting or activated PBMCs were re-stimulated
in the presence of 50 ng/ml of phorbol 12-myristate 13-acetate
(PMA), 1µg/ml ionomycin and 5µg/ml Brefeldin A for 3 h at
37◦C and intracellular cytokine or transcription factor staining
was analysed in CD4+ T-cells. To analyse the extent of T-
cell differentiation to the Th1 phenotype, naive CD4+ T-cells
were purified from PBMCs with the Naive T Cell isolation Kit,
HumanMACS (Miltenyi Biotec). Afterward, cells were incubated
(106 cells/ml) with anti-human CD3 mAb (1µg/ml), anti-human
CD28 mAb (2µg/ml), recombinant IL-2 (5µg/ml), recombinant
IL-12 (2.5 ng/ml) and anti-human IL-4mAb (12.5 ng/ml) all from
Biolegend, in XVIVO-10 medium containing 1% autologous
serum for 5d. Then, cells were re-stimulate with PMA, ionomycin
and brefeldin A during 3 h and the frequency of Th1, Th17, and
Tregs phenotypes was analysed by intracellular immunostaining
of IFN-γ, IL-17, and Foxp3 respectively in the CD4+ T-cell
population. For intracellular staining the following mAbs were
used: PE-Cy7-conjugated anti-IFN-γ mAb (1:100, Biolegend),
APC-Cy7-conjugated anti-IL-17 mAb (1:100, Biolegend) and
PE-conjugated anti-Foxp3 mAb (1:100, Biolegend).
Animals
Ten-to-twelve weeks old C57BL/6 mice were used for all in vivo
experiments. Wild-type (WT) and Foxp3gfp reporter C57BL/6
mice were purchased from The Jackson Laboratory (Bar Harbor,
ME). C57BL/6 Drd3−/−(DRD3KO) mice were kindly donated
by Dr. Marc Caron (25). Foxp3gfp Drd3−/− were generated by
crossing parental mouse strains. We confirmed this new strain to
be transgenic and Drd3-deficient by flow cytometry analysis of
blood cells and PCR of genomic DNA, respectively. Five mice per
cage were housed at 21◦C in a humidity-controlled environment,
on a12/12h light/dark cycle with lights on at 8 a.m., with ad
libitum access to food and water. All mice were maintained
and manipulated according to institutional guidelines at the
pathogen-free facility of the Fundación Ciencia & Vida.
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FIGURE 1 | Alterations in the functional phenotype and DRD3 expression in CD4+ T-cells obtained from Parkinson’s disease patients. (A–C) PBMCs were isolated
from healthy donors (HC) and Parkinson’s Disease patients (PD) and they were immediately analysed or activated with anti-CD3 and anti-CD28 antibodies for 72 h. (A)
Cells were immunostained for several surface markers and DRD3 expression was analysed in different lymphocyte populations by flow cytometry. Left panel shows
the frequency of DRD3+ cells in total CD4+ T-cells (CD3+ CD4+), naïve CD4+ T-cells (CD3+ CD4+ CD45RA+), memory CD4+ T-cells (CD3+ CD4+ CD45RO+),
B-cells (CD19+), and NK cells (CD56+) in resting conditions. Right panel shows the frequency of total CD4+ T-cells (CD3+ CD4+) and memory/effector CD4+ T-cells
(CD3+ CD4+ CD45RO+) after T-cell activation. Two-tailed unpaired Student t-test was used for comparisons between HC (n = 38) and PD (n = 41). **p < 0.01; ***,
p < 0.0001. (B) Resting T-cells or (C) T-cells activated with anti-CD3 and anti-CD28 antibodies for 72 h were stimulated with PMA and ionomycin in the presence of
brefeldin A for 4 h and IFN-γ (left panels), IL-17 (middle panels), and Foxp3 (right panels) expression was determined by intracellular immunostaining in the CD3+
CD4+ gated population. Foxp3+ cells were undetectable in resting conditions. Two-tailed unpaired Student t-test was used for comparisons between HC [n = 9 in
(B); n = 6 in (C)] and PD [n = 11–12 in (B); n = 9 in (C)]. *p < 0.05; **p < 0.01; ***p < 0.0001. (D) Naïve CD4+ T-cells (CD3+ CD4+ CD45RA+) T-cells were isolated
from PBMCs obtained from HC and PD individuals and then they were incubated in Th1-biased conditions for 5 days. Afterwards, cells were stimulated with PMA and
ionomycin in the presence of brefeldin A for 3 h and IFN-γ expression was determined by intracellular immunostaining in the CD3+ CD4+ gated population. Two-tailed
unpaired Student t-test was used for comparisons between HC (n = 7) and PD (n = 6). *p < 0.05.
MPTPp Intoxication and Treatments With
PG01037
Animals were treated as outlined in Figures 2A, 5A.
Groups received 10 intraperitoneal (i.p.) injections of MPTP
hydrochloride (20 mg/kg in saline; Toronto Research Chemicals
INC, Toronto, ON, Canada) and probenecid (250 mg/kg in
saline; Life Technologies, Oregon, USA), administered twice a
week throughout 5 weeks. In all groups receiving MPTP (or the
vehicle) and probenecid, both compounds were administered
in two consecutive injections during the early morning. Some
experimental groups received the i.v. transference of ex vivo
manipulated CD4+ T-cells (as described below) and in other
cases mice received the i.p. administration of PG01037 (30
mg/kg; Tocris Bioscience) as indicated in figure legends.
Viral Transduction
For initial testing of the efficacy of different short hairpin
RNA (shRNA) directed to Drd3 transcription, we generated
HEK293T cells overexpressing stably DRD3. For this purpose,
HEK293T cells were transfected with lentiviral vectors codifying
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FIGURE 2 | Evaluation of the therapeutic potential of CD4+ T-cells treated ex vivo with a DRD3 antagonist in the motor performance of MPTPp-treated mice. (A)
Experimental design: Control animals (without MPTPp treatment) were treated with saline, probenecid, and with or without the i.v. injection of CD4+ T-cells treated ex
vivo with PG01037. MPTPp animals received 10 i.p. injections with MPTP (20 mg/kg) and probenecid (250 mg/kg) during weeks 2–6 (grey arrows). CD4+ T-cells (4 ×
105, 7 × 105, or 10 × 105 per mouse) were treated with or without PG01037 (20 nM) and then i.v. injected in experimental animals 1 day after the first MPTPp
injection (bold red arrow). In some cases, animals received 3 injections of CD4+ T-cells separated by 1 week intervals (bold and thin red arrows). T-cell infiltration was
analysed after 3 weeks of MPTPp-treatment. Neurodegeneration was analysed 1 week after the last MPTPp injection. Motor performance was analysed the week
before beginning with MPTPp administration to distribute experimental groups with homogeneous motor performance and then it was evaluated again 16 h after the
last MPTPp injection in the Beam-test (B) and in the coat-hanger test (C). Experimental groups receiving i.v. injections of CD4+ T-cells are indicated in red bars. Data
represents the mean with the SEM. One-way ANOVA followed by Tukey’s multiple comparison post hoc test were used to determine statistical differences: *p < 0.05
***p < 0.001, n = 5–17 mice per group.
for the reporter gene red fluorescent protein (RFP) followed
by a 2A sequence, puromycin resistance gene and Drd3; the
whole construct under the control of the CMV promoter
(pLenti-GIII-CMV-RFP-2A-Puro-DRD3). Cells were transfected
in the presence of turbofect (Thermo Scientific) and 48h later,
puromycin (3 µg) was added and cells were grown for 28d.
RFP+ cells were isolated by cell-sorting and then used to test
the efficacy of four different shRNA for Drd3 transcription
(shDrd3 1-4). Afterward, HEK293T overexpressing DRD3 (3.5
× 105 cells per point) were transfected with lentiviral vectors
codifying for different versions of shDrd3 or an scrambled
shRNA, followed by green fluorescent protein (GFP) reporter
gene (piLenti-shRNA-GFP). Forty-eight hours later, cells were
lysed and the levels of Drd3 transcripts were quantified
by qRT-PCR.
For silencing DRD3 expression in CD4+ T-cells, we used
the retroviral vector pBullet (26), which was kindly provided
by Dr. Hinrich Abken. We inserted a region encoding GFP,
U6 promoter, shRNA against DRD3 (shDrd3-3; 5
′
-TGC CCT
CTC CTC TTT GGT TTC AAC ACA AC-3
′
) and H1 promoter,
into pBullet vector via NcoI and SalI restriction sites (Genscript,
Piscataway, NJ). pBullet vector drives the expression of the entire
construct by the CMV promoter upstream the NcoI site. This
vector was transfected into Phoenix-AMPHO cells and GFP+
cells were purified by cell sorting to generate a stable cell line
producing shDRD3 retrovirus (RV-shDRD3) in the supernatant
as described before (20). Total CD4+ T-cells were activated with
α-CD3ε mAb 1 µg/ ml, α-CD28 mAb 1 µg/ ml, IL-2 10 ng/ ml
in RPMI medium containing 5% FBS in 6-well plates at 37◦C and
5%CO2 for 96 h. Cells were infected with retroviral particles at 24
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and 48 h of incubation. Infection was carried out by spinoculating
cells with retrovirus in retronectin-coated plates (Takara Bio,
Japan). As a non-silencing control, we transduced CD4+ T-cells
with a control vector (RV-Control) codifying just for GFP. At day
5 of culture, cells were restimulated and transduction efficiency
was determined (GFP+ cells) in CD4+ T-cells by flow cytometry.
Quantitative RT-PCR
Levels ofDrd3 transcripts were quantified as described previously
(20). Briefly, total RNA extracted from cells using the Total
RNA EZNA kit (Omega Bio-Tek), was DNase-digested using
the TURBO DNA-free kit (Ambion) and 1 µg of RNA was
used to synthesize cDNA utilizing M-MLV reverse transcriptase
(Life Technologies). Quantitative gene expression analysis was
performed using Brilliant II SYBR Green QPCR Master Mix
(Agilent). Primers were used at a concentration of 0.5µM.
Expression of Drd3 was normalised to Gapdh. The sequences of
the primers used are the following: Drd3, forward 5n
′
-GAA CTC
CTT AAG CCC CAC CAT-3
′
and reverse 5
′
-GAA GGC CCC
GAG CAC AAT-3
′
; and Gapdh, forward 5
′
-TCC GTG TTC CTA
CCC CCA ATG-3
′
and reverse 5
′
-GAG TGG GAG TTG CTG
TTG AAG-3
′
.
Transference of ex vivo Manipulated
CD4+ T-Cells
Anti-CD3 mAb (100 ng/well) in PBS was pre-incubated in 96-
well plates during 16h at 4◦C and then washed twice with PBS.
Total splenic CD4+ T-cell were isolated by using a negative
selection kit (Miltenyi) and incubated (3 × 106 cells per well)
in anti-CD3-coated 96-well plates containing soluble anti-CD28
mAbs (100 ng/well). Immediately after inducing T-cell activation,
in some cases cells were treated with 20 nM PG01037 for 24 h
and then i.v. injected (4 × 105, 7 × 105, or 1 × 106 cells/mouse)
into recipient mice. In other cases, CD4+ T-cells were transduced
with RV-shDRD3 or RV-Control and then GFP+ cells were
purified by cell-sorting and subsequently i.v. transferred (4× 105
cells/mouse) into recipient mice.
Coat-Hanger Test
To determine the motor performance, we used the coat-hanger
test, which has been validated for detection ofmotor dysfunctions
(27, 28). Briefly, we used a steel coat hanger (diameter: 2mm,
length: 40 cm) suspended at a height of 35 cm from a cushioned
surface. The surface of the coat hanger was marked with regular
sections of 5 cm each. The mice were placed in the middle of the
hanger and the time taken to move from the middle of the hanger
to an extreme was recorded (extreme latency). In addition, the
number of sections by which mice moved though after the first
60 seconds was also determined (# sections).
Beam Test
As a second test to evaluate motor performance we used a
simplified version of the beam test previously described (29).
Briefly, we used a horizontal beam 25 cm length and 3 cm width.
The beam surface was covered by a metallic grid (1 cm2). Mice
were videotaped while traversing the grid-surface beam from one
of the extreme of the beam to the opposite extreme, where the
home-cage was located. Two days of training were performed
for habituation to the task. The number of errors (# errors) was
quantified by watching the videos in slow-motionmode. An error
was defined as when a forelimb or hindlimb slipped through the
grid and became visible between the grid and the beam surface or
on the side of the grid during a forward movement.
Tissue Processing
Animals were sacrificed by transcardial perfusion 48 h after the
last MPTPp injection. For histological techniques, mice were
anesthetised with an overdose of 5% isoflurane (Sigma-Aldrich)
and transcardially perfused with 4% paraformaldehyde (Merck,
Darmstadt, Germany) in 0.125M phosphate buffered saline
(PBS, pH 7.4). Brains were removed and cryoprotected for 48 h
in 20% glycerin and 2% DMSO in PBS. For flow cytometry
analysis, mice were transcardially perfused with PBS instead
paraformaldehyde, brains were rapidly removed, dissected, and
immediately processed for flow cytometry as indicated below.
Histological Techniques and Quantification
Immunohistochemistry was performed on free-floating sections
(40µm thick) and for a given experiment all sections were
processed at the same time with the respective primary antibody.
Sections were washed with PBS and endogenous peroxidase
activity was inactivated by 30min incubation with 0.03% H2O2
in methanol (Sigma-Aldrich). After washing three times with
PBS, the tissue was incubated for 40min with blocking solution
[4% goat serum, 0.05% Triton X-100 (Sigma-Aldrich) and
4% BSA (Merck, Darmstadt, Germany) in PBS], and exposed
overnight to the primary antibodies diluted in blocking solution
at room temperature. The primary antibodies used were:
rabbit anti-tyrosine hydroxylase pAb (TH, 1:1000; Millipore,
Temecula, CA, USA), rat anti-dopamine transporter pAb (anti-
DAT, 1:500; Millipore), rabbit anti-GFAP antibody (1:500; abcam
[EPR1034Y], Cambridge, UK) and rabbit anti-Iba1 antibody
(1:1000; abcam [EPR16588], Cambridge, UK). For colorimetric
immunohistochemistry, antibody binding was detected by
incubating sections with biotinylated goat anti-rabbit pAb (1:500;
Jackson ImmunoResearch Laboratories, West Gore, PA, USA) or
biotinylated goat anti–rat pAb (1:500; Jackson ImmunoResearch
Laboratories, West Gore, PA, USA) in blocking solution for 2 h
at room temperature. The biotinylated antibodies were detected
with peroxidase-conjugated avidin (1:5000; Sigma-Aldrich) for
90min at room temperature followed by incubation with 0.05%
diaminobenzidine (Sigma-Aldrich) in 0.03% H2O2/Trizma-HCl
buffer (pH 7.6). Sections were mounted on glass slides in a
0.2% solution of gelatin in 0.05M Tris (pH 7.6) (Sigma-Aldrich).
The mean number of TH+ neurons from six SN pars compacta
(SNpc) sections (separated by 120µm between each other) per
mouse was quantified under light microscopy at a magnification
of 200X, and the total area of SNpc was calculated using
ImageJ software (National Institutes of Health, Bethesda, MD).
Density of dopaminergic neurons was expressed as the number
of TH+ neurons per area (mm2) in the SNpc. The intensity
of immunostaining of dopaminergic terminals in the striatum
was evaluated within the TH- or DAT–immunoreactive area
(optical density) and was quantified using ImageJ software. To
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evaluate the extent of astrogliosis, the mean of GFAP-associated
immunoreactivity was analysed in areas of interest (660µm x
877µm) in five striatum sections per mouse and quantified as
the integrated density using the Image-J software. To determine
the extent of activated microglia, the mean number of Iba-1high
reactive microglia displaying ameboid shape was quantified in
areas of interest of 660µm x 877µm in five striatum sections
per mouse.
Flow Cytometry Analysis of Mouse T-Cells
Deep cervical lymph nodes and brain sections that contain mid-
brain and striatum from MPTPp-treated mice were minced
and then disaggregated using Collagenase Type IV 1mg/ml
(Gibco, New York, USA) and DNase I 0.25 mg/mL (Roche,
Mammheim, Germany). After enzymatic disaggregation, cells
were passage through 70µm-pore cell-strainer to obtain a single-
cell suspension. The cell suspension was centrifuged in a gradient
of Percoll TM GE Healthcare (Fermelo Biotec) 70%/40%.
The mononuclear cells were extracted from the interface and
resuspended in RPMI 1640 medium supplemented with 10%
FBS. Then, cells were re-stimulated with 50 ng/ml PMA; 1µg/ml
ionomycin and 5µg/ml Brefeldin A for 3 h at 37◦C. To evaluate
the phenotype of T-cells, the mononuclear cells were stained with
fluorochromes-coupled mAbs directed to surface markers, fixed
with formaldehyde 1% and permeabilized with Staining Buffer
Factor Set eBioscienceTM Foxp3/Transcriptm (Thermo Fisher
Scientific). Afterwards, cells were stained with fluorochromes-
coupled mAbs directed to cytokines and transcriptional factors.
The expression of cytokines and transcription factors in different
T-cell subsets was analysed by flow cytometry (FACSCantoII, BD
Bioscience). For surface or intracellular immunostaining, anti-
CD4, anti-TCRγδ, anti-IFN-γ, anti-IL-17, anti-Foxp3, and anti-
RORγt fluorochrome-conjugated mAbs were used at a dilution
of 1:300 (all from Biolegend). For in vitro T-cell activation assays,
effector CD4+ T-cells (Teff; GFP−) and regulatory CD4+ T-
cells (Treg; GFP+) were isolated from the spleen of Foxp3gfp
reporter mice by cell sorting using a FACS Aria II (BD), obtaining
purities over 98%. All in vitro experiments were performed using
complete RPMI medium (supplemented with 10% FBS, 2mM
L-Glutamine, 100 U/mL Penicillin, 100µg/mL Streptomycin
and 50µM β-mercaptoethanol). To assess activation, cells were
stimulated for 6d with 50 ng/well of plate-bound anti-CD3 mAb
and 2µg/mL soluble anti-CD28 mAb on flat-bottom 96-well
plates (Thermo Scientific). IL-2 (10 ng/mL) was added to the
culture at days 0, 3, and 5. To force the Th1 differentiation naive
CD25−CD4+ T-cells were activated in the presence of 20 ng/mL
IL-12, 10 ng/mL IL-2, and 5µg/mL anti-IL-4 for 4d. All analyses
were performed in living cells using the Zombie Aqua (Zaq)
fixable viability kit (Biolegend) in the ZAq− population. Flow
cytometry analysis was performed using a FACS Canto II (BD).
Data were analysed using the FlowJo software (Tree Star).
Statistical Analysis
All values were expressed as mean ± SEM. Differences in
means between PD patients and HC groups were analysed by 2-
tailed unpaired Student’s t-test. Comparisons between different
experimental groups in MPTPp experiments were performed
by one-way ANOVA followed by the multi-comparison Tukey’s
post-hoc test. Correlations between different parameters were
analysed by Pearson’s test when data was normally distributed
or by Spearman’s test when data was not normally distributed.
Normal distribution was determined by Shapiro–Wilk test. P-
value≤ 0.05 was considered significant. Analyses were performed
with GraphPad Prism 6 software.
Study Approval
The study performed with human individuals conforms to the
principles outlined in the Declaration of Helsinki, the study
protocol was approved by the local Ethics Committee of the
Hospital del Salvador, Santiago (Chile), and all the participants
signed a written informed consent before enrollment. All
procedures performed in animals were approved by and
complied with regulations of the Institutional Animal Care and
Use Committee at Fundación Ciencia & Vida.
RESULTS
DRD3 Expression Is Reduced in CD4+
T-Cells Obtained From PD Patients
As stated above, emerging evidence has shown that DRD3-
signalling in CD4+ T-cells plays a pivotal role favouring the
development of PD in animal models (13, 23). Since a previous
study found a significant reduction in the levels of drd3-
transcripts in PBMCs obtained from PD (24), we addressed here
the question of whether DRD3 expression, at the level of protein,
was altered in CD4+ T-cells obtained from PD patients. For this
purpose, we analysed DRD3 expression in different lymphocyte
populations from PD patient samples displaying different stages
of PD progression. Accordingly, we analysed blood samples from
38 HC and 41 PD patients. In these samples we determined
DRD3 expression in different CD4+ T-cells subsets, including
naive CD4+ T-cells, memory CD4+ T-cells, effector CD4+ T-
cells and total CD4+ T-cells. In addition, we also included the
expression of DRD3 in B cells and in natural killer (NK) cells,
as we found high levels of DRD3 expression in these lymphocyte
populations obtained from healthy donors samples (Figure 1A,
left panel). We analysed DRD3 expression in the different
lymphocyte subsets by flow cytometry using the gating strategy
indicated (Supplementary Figure 1). Interestingly, when DRD3
expression was compared in HC and PD patients, we did
not find differences in DRD3 expression in total CD4+ T-
cells (CD3+ CD4+), naive CD4+ T-cells (CD3+ CD45RA+
CD4+), memory/effector CD4+ T-cells (CD3+ CD45RO+
CD4+), B-cells (CD19+) and NK cells (CD56+) upon resting
conditions (Figure 1A, left panel). Conversely, when DRD3
expression was evaluated after ex vivo T-cell activation, DRD3
expression was significantly reduced in total CD4+ T-cells
(CD3+ CD4+) and in memory/effector CD4+ T-cells (CD3+
CD4+ CD45RO+) obtained from PD patients (Figure 1A, right
panel). This data indicates a significant down-regulation of
DRD3 expression in ex vivo activated CD4+ T-cells obtained
from PD patients. We next attempted to evaluate whether
DRD3 down-regulation was associated with PD activity. For
this purpose, we analysed the potential correlations between
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DRD3 expression and the clinical score of PD patients evaluated
by different tests, including the UPDRS, the Modified Hoehn
and Yahr scale, the Schwab and England score and the MoCA
test. Interestingly, we found a significant correlation between
DRD3 down-regulation in naïve CD4+ T-cells and the UPDRS
clinical score (Supplementary Figure 2), although we did not
find significant associations of disease activity with the DRD3
down-regulation in activated total or memory/effector CD4+
T-cells (Supplementary Figure 3).
CD4+ T-Cells Obtained From PD Patients
Display an Increased Percentage of
Pro-inflammatory Phenotypes and Biased
Th1-Differentiation
DRD3-signalling in CD4+ T-cells has been consistently
associated to Th1 and Th17 mediated immunity (13, 19, 20).
Furthermore, Th1 and Th17 have been proven to be
the inflammatory phenotypes of CD4+ T-cells driving
neuroinflammation and consequent neurodegeneration of
dopaminergic neurons in animal models of PD (6, 13). On the
other hand, it has been demonstrated that suppressive activity
of Tregs is able to dampen T-cell mediated inflammation in PD
models, thus attenuating neurodegeneration (6, 30, 31). For
these reasons, we next aimed to determine potential alterations
in the percentage of inflammatory T-cell phenotypes Th1 and
Th17 as well as in the extent of the anti-inflammatory T-cell
phenotype, Treg, obtained from PD patients in comparison to
HC. Accordingly, in a subgroup of PD and HC we first analysed
the functional phenotypes in resting T-cells. For this purpose,
immediately after isolation from fresh blood samples, PBMC
were stimulated with PMA and ionomycin for 4h and cytokine
production and the expression of key transcription factors were
analysed by intracellular immunostaining followed by flow
cytometry analysis. These analyses in “resting” conditions (after
just a short period of stimulation) were performed to have an
idea of the frequency of inflammatory and anti-inflammatory
phenotypes contained in the population of memory and effector
T-cells. The results show that PD individuals presented 2-fold
higher Th1 frequency in resting CD4+ T-cells in comparison
with HC (Figure 1B). On the other hand, Th17 frequency in
resting CD4+ T-cells was similar in PD and HC, whilst Tregs
were not detectable in these conditions (Figure 1B and data not
shown). To allow the expansion of T-cells, we next analysed the
frequency of relevant functional phenotypes of CD4+ T-cells
after the activation with anti-CD3 and anti-CD28 antibodies
for 3d. Then, activated T-cells were re-stimulated with PMA
and ionomycin during the last 4h and cytokine production
and the expression of transcription factors were quantified
by intracellular immunostaining followed by flow cytometry
analysis. The results show about 3-fold increase in the frequency
of both Th1 and Th17 phenotypes in ex vivo activated CD4+
T-cells obtained from PD patients in comparison with those
obtained from HC (Figure 1C). Of note, in these conditions
Tregs were detectable, although no differences were observed
between PD patients and HC (Figure 1C). We also analysed
the potential association of Th1, Th17, Treg, or total CD4+
T-cells frequencies in peripheral blood of PD patients with the
severity of the disease, however we did not find any significant
correlation (Supplementary Figure 4). Since we observed a
higher difference in Th1 frequency between PD and HC after ex
vivo T-cell activation (Figure 1C) than when compared in resting
conditions (Figure 1B), we wondered whether naive CD4+
T-cells differentiating to Th1 phenotype could be contributing
to this higher Th1 frequency. To address this possibility, we
performed experiments in which naive CD4+ T-cells were first
isolated by cell-sorting, cultured in Th1-skewed conditions and
then the extent of Th1 differentiation was compared between
PD patients and HC. Interestingly, these results show a 2-fold
increase of Th1 differentiation in PD patients in comparison
with HC (Figure 1D). Taken together these results indicate
that CD4+ T-cells in PD patients present higher frequencies
of pro-inflammatory phenotypes and naive cells display a
skewed Th1-differentiation.
The Transference of CD4+ T-Cells Treated
ex vivoWith a Selective DRD3-Antagonist
Exerts a Therapeutic Effect Attenuating
Motor Impairment in MPTPp-Treated Mice
Since a prominent role of DRD3-signalling in CD4+ T-cells
has been observed in the development of PD in mouse models
(13, 32), and the systemic DRD3-antagonsim has been proven to
attenuate neurodegeneration and motor impairment in different
animal models of PD (23), we next aimed to test the therapeutic
potential of the selective inhibition of DRD3-confined to CD4+
T-cells. For this purpose, we used an animal model of PD
induced by the chronic administration of MPTP and probenecid
(MPTPp), which results in both, loss of dopaminergic neurons
of the nigrostriatal pathway and a significant motor impairment
(33). To exert a selective DRD3-antagonism in CD4+ T-
cells, these cells were pre-incubated ex vivo with PG01037
(hereinafter called CD4+/PG01037) (34) and then transferred
into MPTPp-treated mice. Of note, DRD3-antagonism mediated
by PG01037 20 nM attenuated the potentiation of Th1-
differentiation exerted by the selective stimulation of DRD3
with dopamine 50 nM (Supplementary Figure 5). Accordingly,
we performed a titration of the number of injections and
the number of CD4+ T-cells per injection able to exert a
significant therapeutic effect on MPTPp-treated mice. For this
purpose, CD4+ T-cells were incubated with PG01037 20 nM
ex vivo and then, 4x105, 7x105 or 10x105 CD4+ T-cells per
mouse were transferred in a single i.v. injection into MPTPp
mice. Moreover, another group of mice was treated with three
injections (separated by 7d between) of 4x105 CD4+ T-cells
per mouse each (Figure 2A). We also used a control group
of mice that received CD4+ T-cells without ex vivo treatment
with PG01037. In all experimental groups we determined the
therapeutic potential at the level of motor impairment and
neurodegeneration and the extent of participation of different T-
cell subsets into the midbrain and cervical lymph nodes (CLN).
Notably, the results show that only a single injection of 4 × 105
CD4+/PG01037, but not single injections of 7× 105 or 10× 105
or three injections of 4× 105 CD4+/PG01037 per mouse, exerted
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significant attenuation of motor impairment as determined by
the beam test (# errors; Figure 2B) and the coat-hanger test
(extreme latency; Figure 2C). Thus, these results indicate that the
treatment of MPTPp-intoxicated mice with a single injection of
4 × 105 CD4+/PG01037 exerts a therapeutic effect at the level of
motor impairment in this animal model.
To determine how the different regime of treatment of
MPTPp mice with the transfer of ex vivo manipulated CD4+
T-cells affected the participation of different T-cell subsets into
the midbrain and CLN, we first determine the time-point in
which neuroinflammation was already evident in this animal
model. Accordingly, we evaluated the dynamics of M1 and M2
phenotypes in microglial cells in the brain and the extent of
T-cell infiltration in meningeal vessels at different time-points
in MPTPp animals. We observed that both, meningeal CD4+
T-cells and M1-microglia were already increased after 3 weeks
of MPTPp treatment (Supplementary Figure 6) and thereby we
chose this time-point to analyse the phenotypes of CD4+ T-
cells infiltrating the midbrain and CLN. Interestingly, the results
show that the single injection of 4× 105 CD4+/PG01037 was the
only treatment that did not reduce the number of mononuclear
cells infiltrating the midbrain of MPTPp mice (Figures 3A,B),
coinciding with the therapeutic effect observed at the level of
motor impairment. Conversely, at the level of T-cells infiltrating
CLN, all the therapeutic regime of transfer of CD4+/PG01037
in MPTPp-intoxicated mice resulted in significant reduction
of alive lymph nodes cells (Figures 3C,D). Moreover, single
injections of 4 × 105 or 10 × 105 or three injections of 4 ×
105 CD4+/PG01037, but not the single injection of 7 × 105
CD4+/PG01037 significantly attenuated the number of CD4+
T-cells infiltrating the CLN in MPTPp mice (Figures 3C,D).
Interestingly, only a single injection of 10 × 105 or three
injections of 4 × 105 CD4+/PG01037 resulted in attenuated
number of Th1 and Th17 in the CLN ofMPTPp-intoxicatedmice
FIGURE 3 | Analysis of T-cell infiltration into the brain and cervical lymph nodes in MPTPp-intoxicated mice after transference of CD4+ T-cells treated with PG01037
ex vivo. Animals were treated as described in Figure 2A and sacrificed after 3 weeks of MPTPp intoxication (at the end of week number 4 in the scheme of
Figure 2A). The frequencies of different inflammatory and anti-inflammatory lymphocyte subsets infiltrating the midbrain (A,B) and cervical lymph nodes (C,D) were
analysed by flow cytometry. (A,C) Representative dot plots showing the gating strategy. (B,D) absolute numbers per animal of different lymphocyte subsets obtained
from the different experimental groups were quantified. Data represent the mean with the SEM. One-way ANOVA followed by Tukey’s multiple comparison post-hoc
test was used to determine statistical differences: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; n = 3 mice per group.
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(Figures 3C,D). In addition, any of the treatments proven show
a significant difference in the extent of Tregs infiltrating CLN
in MPTPp mice (Figures 3C,D). Thus, unexpectedly, the only
difference at the level of T-cells infiltrating midbrain and CLN
that was associated with the selective therapeutic effect at the
level of motor impairment was the absence of reduction in the
number of total mononuclear cells infiltrating the midbrain of
MPTPp mice. To address a potential effect of DRD3-signalling in
the viability of CD4+ T-cells, we isolated CD4+ T-cells from the
spleen of WT or DRD3-defficient mice and then were activated
for 6d and subsequently the viability was analysed in Teff and
Treg cells by flow cytometry. The results show no significant
differences in the frequency of living Treg or Teff between
both genotypes (Supplementary Figure 7), thus ruling out the
possibility that DRD3-signalling affected CD4+ T-cells viability.
Finally, to determine the therapeutic potential of the different
regime of T-cell transfer at the level of neurodegeneration, we
next quantified the loss of dopaminergic neurons in the SN
and the extent of dopaminergic terminals in the striatum of
experimental mice. For this purpose, after the determination
of motor performance, mice were sacrificed and dopaminergic
neurons were quantified by immunohistochemical analysis of
tyrosine hydroxylase (TH) in the SN pars compacta (SNpc)
and the density of dopaminergic terminals was evaluated in
the striatum by immunohistochemical analysis of dopamine
transporter (DAT). Quite unexpected, the results show that the
extent of neurodegeneration was not significantly attenuated
by any of the regime of ex vivo manipulated T-cell transfer
(Figure 4). Taken together these results indicate that a single
injection of 4× 105 CD4+/PG01037 exerts a therapeutic effect in
MPTPpmice attenuatingmotor impairment but without effect in
the extent of neurodegeneration.
The ex vivo Transcriptional Inhibition of
Drd3 in CD4+ T-Cells Does Not Exert Any
Therapeutic Effect in MPTPp-Treated Mice
Because the pharmacologic DRD3-antagonism of CD4+ T-
cells ex vivo exerted a therapeutic effect only at the level of
motor impairment but not at the level of neurodegeneration
we attempted to improve the therapeutic power inducing
a more sustained inhibition of DRD3-signalling in CD4+
T-cells. For this purpose, we generated retroviral particles
codifying for an shRNA to interfere with Drd3-transcription
(shDRD3). After setting up the transduction protocols, we
confirmed that retroviral transduction with the shDRD3 (RV-
shDRD3) actually reduced the levels of Drd3-transcripts and
resulted in impaired production of IFN-γ by CD4+ T-cells
(Supplementary Figure 8), as described before (20). Afterwards,
we performed a set of experiments aimed to compare the
therapeutic potency of the transfer of CD4+/PG01037, the
transfer of CD4+ T-cells ex vivo transduced with RV-shDRD3
(hereinafter called CD4+/RV-shDRD3) or the systemic DRD3-
antagonism. For this purpose, MPTPp-intoxicated mice received
a single injection of 4 × 105 CD4+/PG01037, a single injection
of 4 × 105 CD4+/RV-shDRD3 or the i.p. administration of
PG01037 at 30 mg/kg and the extent of neurodegeneration,
motor impairment and T-cell phenotypes in midbrain and CLN
were determined (Figure 5A). The results show that only the
transfer of CD4+/PG01037 or the systemic administration of
PG01037, but not the transfer of CD4+/RV-shDRD3 exerted
a significant attenuation of motor impairment in MPTPp-
intoxicated mice reducing the number of errors in the beam
test (Figure 5B) and increasing the number of sections travelled
in the coat-hanger test (Figure 5C). It is noteworthy that in
a previous study using the same animal model of PD, we
show that a single i.p. injection of 30 mg/kg PG01037 had no
effect in motor impairment (23). Since the remaining PG01037
concentration present in CD4+/PG01037 (after the ex vivo
treatment with 20 nM PG01037 followed by cells washing) is
much lower than that present in a single i.p. injection of 30
mg/kg PG01037, it is tempting to rule out that the therapeutic
effect exerted by CD4+/PG01037 in motor impairment is
independent of CD4+ T-cells and just due to PG01037. The
analysis of T-cell phenotypes in midbrain and CLN did not
give any significant differences, despite they show interesting
trends for the treatment with systemic PG01037 in decreasing
Th1 and Th17 frequencies and increasing Tregs frequency in
CLN of MPTPp-intoxicated mice (Supplementary Figure 9).
Consistently with previous results (23), the quantification of
dopaminergic neurons of the nigrostriatal pathway shows a
significant reduction in neuronal loss only when MPTPp-
intoxicated mice were treated with systemic PG01037, but not
when received the transfer of CD4+/PG01037 or CD4+/RV-
shDRD3 (Figure 6). Together, these results indicate that whereas
the systemic DRD3-antagonism exerts a therapeutic effect
attenuating neurodegeneration and motor impairment, the
transfer of CD4+/PG01037 exerts a therapeutic effect only
confined to the motor impairment but without effect in neuronal
loss. Quite unexpectedly, the transfer of CD4+/RV-shDRD3 did
not exert any detectable therapeutic effect. A summary of the
different therapeutic effects observed for the different treatments
in different set of experiments carried out in this study is shown
in Table S1.
The Systemic DRD3-Antagonism as Well as
the Transference of CD4+ T-Cells Treated
ex vivoWith a Selective DRD3-Antagonist
Reduce the Extent of Microglial Activation
in MPTPp-Treated Mice
To gain a deeper insight in the mechanism involved in the
therapeutic effect exerted by the systemic DRD3-antagonism
and by the transfer of CD4+/PG01037 in MPTPp-treated
mice, we next attempted to analyse how was affected astrocyte
and microglial activation. For this purpose, MPTPp-intoxicated
mice received a single injection of 4 × 105 CD4+/PG01037,
or the i.p. administration of PG01037 at 30 mg/kg (as
indicated in Figure 5A) and the extent of astrogliosis and
microglial activation were evaluated in the striatum by
immunohistochemical analyses of GFAP and Iba1, respectively.
Unexpectedly, the results show no differences in the degree of
astrogliosis among the different experimental groups (Figure 7).
On the other hand, both the systemic DRD3-antagonism and
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FIGURE 4 | Evaluation of the therapeutic potential at the level of neurodegeneration of DRD3 inhibition in CD4+ T-cells by treatment with a selective antagonist ex
vivo in MPTPp-treated mice. CD4+ T-cells (4 × 105, 7 × 105, or 10 × 105 per mouse) were treated with or without PG01037 (20 nM) and then i.v. injected in
experimental animals 1 day after the first MPTPp injection (see Figure 2A). In some cases, animals received 3 injections of CD4+ T-cells separated by 1 week
intervals. Neurodegeneration was analysed 1 week after the last MPTPp injection. Dopaminergic neurons were quantified by immunohistochemical analysis of tyrosine
hydroxylase (TH) in the substantia nigra pars compacta (SNpc) (A) and dopamine transporter (DAT) in the striatum (B). Data represent the mean with the SEM.
One-way ANOVA followed by Tukey’s multiple comparison post-hoc test was used to determine statistical differences: *p < 0.05; ****p < 0.0001; n = 5–8 mice per
group.
the transfer of CD4+/PG01037 induced a marked reduction in
the extent of microgliosis in MPTPp-treated mice (Figure 7).
Thus, these results show that the therapeutic effect observed for
systemic DRD3-antagonism at the level of neurodegeneration
and motor impairment and for the transfer of CD4+/PG01037
at the level of motor impairment involve an attenuation in
microglial activation.
DISCUSSION
Our data here demonstrates a significant and selective reduction
of DRD3-expression confined to CD4+ T-cells obtained from PD
patients. Moreover, our results indicate that the pharmacologic
DRD3-antagonism, but not the interference of Drd3-trascription
in CD4+ T-cells ex vivo resulted in a therapeutic effect at the
level of motor impairment. However, only systemic DRD3-
antagonism, but not the transfer of CD4+/PG01037, reduced the
extent of neurodegeneration of the dopaminergic neurons of the
nigrostriatal pathway.
Interestingly, our results show a significant reduction of DRD3
expressed in CD4+ T-cells, which could be due to a compensatory
mechanism attempting to decrease the inflammatory effect
induced by DRD3-stimulation in this lymphocyte population
(13). Moreover, this alteration on DRD3 expression in CD4+
T-cells obtained from PD patients could represent a useful
marker for diagnostic analysis. Of note, Nagai et al., described
before that the levels of Drd3 mRNA were decreased in
total PBMCs obtained from PD patients and the degree of
this down-regulation was correlated with the stage of disease
progression (24). Accordingly, we found a significant correlation
between DRD3 down-regulation (at the protein level) in
naive CD4+ T-cells and the degree of disease activity (see
the UPDRS score in Supplementary Figure 2). Of note, we
did not find significant associations of disease activity with
the DRD3 down-regulation in any other lymphocyte subset
analysed, including B-cells, NK cells, resting or activated total
CD4+ T-cells and activated memory/effector CD4+ T-cells
(Supplementary Figure 2, 3). Thus, these results suggest a
selective association of clinical PD progression with the extent
of down-regulation of DRD3 expression selectively on naive
CD4+ T-cells.
Despite our previous results obtained in mouse models
indicate that DRD3-signalling in CD4+ T-cells favours the
development of PD (13), our results obtained from PD patients
show a significant and selective reduction of DRD3 expression
in CD4+ T-cells obtained from peripheral blood in comparison
to those obtained from HC (Figure 1). Thus, this reduction of
DRD3 expression in CD4+ T-cells obtained from PD patients
could be interpreted as an adaptive down-regulation of this
pro-inflammatory receptor after a long-term period of chronic
inflammation in these patients. Nevertheless, another plausible
explanation for this fact can be that simply, CD4+ T-cells
specific for relevant antigens associated to PD [i.e., nitrated α-
synuclein; (1, 35)] would acquire inflammatory phenotypes with
high DRD3-expression (20) and they would be just infiltrating
the site of inflammation (into the SNpc) but not recirculating
in the periphery. This fact would explain why CD4+ T-cells
expressing low levels of DRD3 would be selectively found in the
periphery. This latter hypothesis highlights the advantages that
should have an antigen-specific therapy based in CD4+ T-cells
as a treatment for PD. In this regard, it is expected that a therapy
involving the inhibition of DRD3 confined only to those CD4+ T-
cells specific for relevant antigens associated to PD (i.e., nitrated
α-synuclein) would exert a stronger therapeutic potential than
those therapeutic approaches tested here involving the inhibition
of DRD3-signalling in CD4+ T-cells irrespective of their antigen-
specificity. Furthermore, an antigen-specific CD4+ T-cell based
therapy for PD would avoid the multiple potential side-effects
exerted by systemic administration of dopaminergic drugs, such
as PG01037.
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FIGURE 5 | Comparison of the therapeutic potential of the systemic DRD3-antagonistm or the intravenous transference of CD4+ T-cells transduced with shRNA for
DRD3 or treated with a DRD3 antagonist on the motor performance of MPTPp-treated mice. (A) Experimental design: Control animals (without MPTPp treatment)
were treated with saline and probenecid alone, or with i.p. PG01037, or the i.v. transference of CD4+ T-cells treated with PG01037, transduced with RV-Control or
transduced with RV-shDRD3. MPTPp animals received 10 i.p. injections with MPTP (20 mg/kg) and probenecid (250 mg/kg) during weeks 2–6 (grey arrows). CD4+
T-cells (4 × 105 cells per mouse) were treated with 20 nM PG01037 (red) or transduced with retroviral particles (MOI 1:1) codifying for RV-Control or RV-shDRD3 (blue)
and then i.v. injected in experimental animals 1 day after the first MPTPp injection. Mice treated with systemic DRD3-antagonism (green) received 9 i.p. injections of
PG01037 (30 mg/kg) administered 1 day after MPTPp injections starting after the second MPTPp administration. T-cell infiltration was analysed after 3 weeks of
MPTPp-treatment. Neurodegeneration was analysed 1 week after the last MPTPp injection. Motor performance was analysed the week before beginning with MPTPp
administration to distribute experimental groups with homogeneous motor performance and then it was evaluated again 16 h after the last MPTPp injection in the
Beam-test (B) and in the coat-hanger test (C). Data represents the mean with the SEM. One-way ANOVA followed by Tukey’s multiple comparison post hoc test were
used to determine statistical differences: *p < 0.05, **p < 0.01, ****p < 0.0001, n = 5–12 mice per group.
Importantly, we found that naive CD4+ T-cells obtained
from Chilean PD patients display an increased differentiation
toward Th1, a functional phenotype that has been involved
in the inflammatory response associated to neurodegeneration
in animal models (6, 13). In the same direction, in an study
performed in a cohort of 82 Italian PD patients, Kustrimovic et
al., have performed an analysis of the different functional T-cell
phenotypes and have described an Th1-biased immune signature
in both, drug-naive or drug-treated PD (36). In addition, another
previous study carried out with 40 Italian PD patients has shown
a positive correlation between the degree of PD progression with
the levels of IFN-γ produced by PBMCs (37). Thereby, together
these results suggest that this Th1-skewed differentiation of naive
CD4+ T-cells is a general feature of PD patients, irrespective
of their ethnicity and independent on the administration of
dopaminergic drugs.
The present findings indicate that both, the systemic DRD3-
antagonism as well as the transfer of CD4+/PG01037 attenuated
themotor impairment induced byMPTPp-intoxication, however
the systemic treatment with PG01037 was the only therapeutic
approach that reduced the loss of dopaminergic neurons in
the SNpc. This differential therapeutic effect exerted by the
systemic DRD3-antagonism in comparison to the transfer of
CD4+/PG01037 could be due to that systemic administration
of PG01037 would be able to block DRD3-signalling not only
in CD4+ T-cells, but also in astrocytes. In this regard, we
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FIGURE 6 | Comparison of the therapeutic potential of the systemic DRD3-antagonistm or the intravenous transference of CD4+ T-cells transduced with shRNA for
DRD3 or treated with a DRD3 antagonist on neurodegeneration of MPTPp-treated mice. CD4+ T-cells (4 × 105 cells per mouse) were treated with 20 nM PG01037
(red) or transduced with retroviral particles (MOI = 1) codifying for RV-Control or RV-shDRD3 (blue) and then i.v. injected in experimental animals 1 day after the first
MPTPp injection. Mice treated with systemic DRD3-antagonism (green) received 9 i.p. injections of PG01037 (30 mg/kg) administered 1 day after MPTPp injections
starting after the second MPTPp administration (see scheme in Figure 5A). Neurodegeneration was analysed 1 week after the last MPTPp injection. Dopaminergic
neurons were quantified by immunohistochemical analysis of tyrosine hydroxylase (TH) in the substantia nigra pars compacta (SNpc) (A) and dopamine transporter
(DAT) in the striatum (B). Data represent the mean with the SEM. One-way ANOVA followed by Tukey’s multiple comparison post-hoc test were used to determine
statistical differences: *p < 0.05; ****p < 0.0001 n = 5–7 (A) or n = 5–11 (B) mice per group.
have obtained evidence suggesting that DRD3-inhibition in
astrocytes favours an anti-inflammatory astrogliosis, which was
associated with reduced number of inflammatory microglia (23).
Accordingly, in the present study we observed that both the
systemic DRD3-antagonsim and the transfer of CD4+/PG01037
decreased the number of inflammatory microglia, but without
apparent effect in astrocyte activation (Figure 7). In addition
to astrocytes and CD4+ T-cells, DRD3 has been described
to be expressed in other subsets of immune cells that could
play a relevant role in neuroinflammation associated to PD,
including B-cells, NK cells, and neutrophils (38). In this regard,
auto-antibodies recognising Lewy bodies and dopaminergic
neurons have been detected in the serum and infiltrated in
the brain parenchyma of PD patients (39). Furthermore, the
stereotaxic delivery of IgG purified from PD patients induces
a significant loss of dopaminergic neurons of the SN in
rats in comparison with the effect observed for IgG purified
from HC, thus suggesting a relevant role of B-cells in the
physiopathology of PD (40). On the other hand, it has been
described a significant reduction in the expression of the NK
inhibitory receptor NKG2A in PD (41). Moreover, a recent meta-
analysis performed with 943 patients indicated an association
of PD with increased number of NK cells (42), suggesting a
role for NK cells in the physiopathology of this disorder. In
addition, Th17 cells, which have been consistently involved in
PD (6, 43, 44) exert their effector function mainly by recruiting
neutrophils to the site of inflammation, where they release
cytotoxic granules inducing directly the death of target cells
(45). Thus, DRD3 expressed in neutrophils, B-cells or NK cells
could potentially also play a role promoting PD development
and progression, nevertheless, further studies are necessaries to
address experimentally the relevance and relative contribution of
these potential mechanisms in PD.
Intriguingly, the i.v. transfer of CD4+/PG01037 into MPTPp-
treated mice, reduced the motor impairment but without
significant effects in neurodegeneration. This discrepancy could
be due to that, by affecting IL-4 and IFN-γ production (20),
DRD3-signalling in CD4+ T-cells might be involved in the cross-
talk between T-cell function and neuronal tasks, irrespective
of the neurodegenerative process. In this regard, it has been
previously shown that IL-4-produced by CD4+ T-cells might
regulate the acquisition of spatial memory in the hippocampus
(46). Whether DRD3-signalling in CD4+ T-cells may affect
neural circuitry involved in motor performance or not should be
addressed in further studies.
Intriguingly, when we tested the therapeutic potential of the
transfer of increasing number of CD4+/PG01037 into MPTPp-
mice, we did not observe a dose-response curve. Unexpectedly,
we obtained a therapeutic effect only with the lower dose of
CD4+/PG01037 (4 × 105 cells per mouse), but not with higher
doses of T-cells (7× 105 or 10× 105 cells per mouse). According
to these results, it has been previously shown that the transfer
of low dose of CD4+ T-cells (5 × 104 cells per mouse) exerts
a stronger effect than higher doses of CD4+ T-cells in an anti-
tumour therapy (47). In this regard, it is though that the transfer
of lower doses of therapeutic CD4+ T-cells allows a stronger
expansion in vivo after antigen-recognition.
Unexpectedly, whereas the DRD3-antagonsim confined
to CD4+ T-cells exerted a significant attenuation of motor
impairment in MPTPp-treated mice, the transcriptional
inhibition of Drd3 in CD4+ T-cells had no effect in motor
impairment. This apparent controversy among our results
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FIGURE 7 | Analysis of neuroinflammation in MPTPp-intoxicated mice upon treatment with systemic DRD3-antagonism or with the intravenous transference of CD4+
T-cells treated with a DRD3 antagonist. CD4+ T-cells (4 × 105 cells per mouse) were treated with 20 nM PG01037 (red) and then i.v. injected in experimental animals
1 day after the first MPTPp injection. Mice treated with systemic DRD3-antagonism (green) received 9 i.p. injections of PG01037 (30 mg/kg) administered 1 day after
MPTPp injections starting after the second MPTPp administration (see scheme in Figure 5A). Neuroinflammation was analysed 1 week after the last MPTPp injection.
Astrogliosis was quantified by immunohistochemical analysis of GFAP and microglial activation was quantified by immunohistochemical analysis of Iba1 in the
striatum. Representative overview images of GFAP (top panel) and Iba1 (middle panel) immunostaining are shown. Quantification of GFAP-associated density
(bottom-left panel) and the number of Iba1high cells per area (bottom-right panel) are shown in the bottom panels. Data represent the mean with the SEM from 3 to 5
mice per group. One-way ANOVA followed by Tukey’s multiple comparison post-hoc test were used to determine statistical differences: ***p < 0.001; ****p < 0.0001.
could be due to the different extent of DRD3 inhibition. In this
regard, DRD3-antagonism in CD4+ T-cells was performed with
20 nM PG01037, a concentration that represents approximately
28-fold its Ki (34). Thereby, the conditions used to promote
DRD3-antagonism ensure the inhibition of nearly all DRD3
expressed in CD4+ T-cells. On the other hand, despite
CD4+/RV-shDRD3 displayed a significant impairment in
the production of IFN-γ (Supplementary Figure 8E), the
reduction exerted in the levels of drd3-transcripts was about
50% (Supplementary Figure 8D). Thereby, it is likely that this
milder effect in DRD3-inhibition exerted by CD4+ T-cells
transduction with RV-shDRD3 would explain why we could not
observe any detectable therapeutic effect at the level of motor
impairment or neurodegeneration. At this point, it is important
to note that upon T-cell activation, DRD3 expression was
sharply reduced in CD4+ T-cells (Supplementary Figure 10),
although the levels of drd3 transcripts were increased (20).
These results suggest that DRD3-mediated effects are triggered
in resting conditions or early after CD4+ T-cell activation, but
with consequences later in T-cell response. Moreover, since
T-cell activation is required to promote retroviral transduction
in CD4+ T-cells, we could not observe a significant effect
of shDRD3 transduction on DRD3 expression in activated
CD4+ T-cells (Supplementary Figure 10). Thus, a plausible
explanation for the lack of therapeutic effect observed for the
transfer of CD4+ T-cells transduced ex vivo with RV-shDRD3
is that an early inhibition of DRD3-signalling in resting CD4+
T-cells is necessary to evoke the beneficial effects induced in
motor impairment in MPTPp-treated mice.
It is intriguing that our previous study evaluating the
therapeutic potential of systemic administration of PG01037
shows a significant increase in anti-inflammatory astrogliosis and
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attenuation of neurodegeneration of the nigrostriatal pathway
at the level of neuronal bodies in the SNpc and at the level of
dopaminergic terminals in the striatum (23), however the present
study shows just a therapeutic effect at the level of SNpc, but
not in the striatum and without effect in astrocyte activation
(Figures 4, 7). This discrepancy could be explained by the fact
that these two set of experiments were performed in two different
animal facilities, and therefore the microbiota composition of
experimental mice should be different as well. In this regard,
it has been recently demonstrated that gut microbiota has a
strong impact in the susceptibility of individuals to develop
neurodegeneration and the motor impairment associated to PD
in humans and animal models (48).
Finally, it is important to note that the treatments that exerted
therapeutic effects here, the systemic PG01037 administration
and the i.v. transfer of CD4+/PG01037, were administered early
during the induction of the disease (24 h after the secondMPTPp
injection and 24 h after the first MPTPp injection, respectively).
Despite these treatments were given before the motor onset,
early diagnosis of PD in humans is currently quickly evolving.
Indeed, there are some key early symptoms, including REM sleep
disorder, olfactory loss (49), and gut-associated issues (50) that
together might predict PDmanifestation and the development of
motor impairment with many years in advance. In this regard,
drug-design is currently pointing to stop the progression of
neurodegeneration in PD at early stages of diagnosis, earlier than
the onset of motor impairment.
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